Fig. 5

AGR-H19-Rgof enhances animal muscle mass. a Graphic illustration of AGR-H19-Rgof and experimental settings. b Representative pictures of AGR-Scr or AGR-H19-Rgof-treated muscle pieces. c Weights of individual indicated muscles from mice with indicated treatment. Mean±SD, n = 5, 6, 8 animals, one-way ANOVA. d Weights of BAT, WAT, or VAT from mice with indicated treatment. Mean±SD, n = 5, 6, 8 animals, one-way ANOVA. e Representative images of lean, fat, and bone tissues by the dual-energy x-ray absorptiometry imaging system from mice with indicated treatment. f Quantification of body weight, lean weight, and fat weight by the dual-energy x-ray absorptiometry imaging system from mice with indicated treatment. Mean ± SD, n = 5 animals per experimental group, Student’s t test. g Immunofluorescence staining using the indicated antibodies of TA. Scale bars, 100 μm. h, i Statistical analysis of staining intensities of DMD (h, left), β-dystroglycan (h, right) or DRP2 (i, left), or nNOS (i, right) of TA. Mean ± SD, n = 8 animals per experimental group, Student’s t test